Dexcom Reports Third Quarter 2026 Results and Authorizes $1.0 Billion Share Repurchase Program
Dexcom reported third-quarter 2026 revenue of $1.344 billion, representing an 11% increase year-over-year, alongside GAAP operating income of $327.2 million. The company raised its full-year 2026 revenue guidance midpoint to between $5.20 billion and $5.25 billion and announced a new $1.0 billion share repurchase program. For shareholders, these results reflect continued top-line growth, margin expansion, and capital return initiatives.
Key points
- Worldwide revenue grew 11% year-over-year to $1.344 billion for the third quarter ended September 30, 2026.
- GAAP operating income reached $327.2 million, or 24.3% of revenue, compared to $242.5 million in the third quarter of 2025.
- The Board of Directors authorized a share repurchase program of up to $1.0 billion of common stock expiring no later than December 31, 2027.
- Full-year 2026 revenue guidance was raised to a range of $5.20 billion to $5.25 billion.
The filing
Written by AI (Google Gemini, gemini-3.5-flash-lite) on Oct 30, 2026, 8:17 AM ET, from the text of the filing and its press-release exhibits only.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.